Pharmaceutical

STAT+: Stephen Hemsley, UnitedHealth Group board chair, sells nearly $113 million in stock

STAT+: Stephen Hemsley, UnitedHealth Group board chair,...

Dec 7, 2023

Stephen Hemsley, the board chair and former CEO of UnitedHealth Group, has sold ...

Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents

Most drugmakers have so far ignored looming FTC deadlin...

Dec 7, 2023

Only one company has responded to an FTC demand for several drugmakers to delist...

STAT+: Biden proposal targeting pharma patents spurs industry fears and consumer doubts

STAT+: Biden proposal targeting pharma patents spurs in...

Dec 7, 2023

The Biden administration's assertion of its authority to exercise "march-in" rig...

LY-3885125 by Eli Lilly and Co for Dyslipidemia: Likeli...

Dec 6, 2023

LY-3885125 is under clinical development by Eli Lilly and Co and currently in Ph...

Tislelizumab by BeiGene for Gastric Cancer: Likelihood ...

Dec 6, 2023

Tislelizumab is under clinical development by BeiGene and currently in Phase III...

IGM jettisons workforce and blood cancer programme to refocus pipeline

IGM jettisons workforce and blood cancer programme to r...

Dec 6, 2023

IGM Biosciences plans to axe 22% of its workforce, becoming the latest company ...

Tislelizumab by BeiGene for Esophageal Squamous Cell Ca...

Dec 6, 2023

Tislelizumab is under clinical development by BeiGene and currently in Pre-Regis...

Tislelizumab by BeiGene for Gastroesophageal (GE) Junct...

Dec 6, 2023

Tislelizumab is under clinical development by BeiGene and currently in Phase III...

DB-1310 by Duality Biologics (Shanghai) for Solid Tumor...

Dec 6, 2023

DB-1310 is under clinical development by Duality Biologics (Shanghai) and curren...

Sirolimus by OrphAI Therapeutics for Bronchiolitis Obli...

Dec 6, 2023

Sirolimus is under clinical development by OrphAI Therapeutics and currently in ...

Sirolimus by OrphAI Therapeutics for Pulmonary Arterial...

Dec 6, 2023

Sirolimus is under clinical development by OrphAI Therapeutics and currently in ...

DB-1310 by Duality Biologics (Shanghai) for Non-Small C...

Dec 6, 2023

DB-1310 is under clinical development by Duality Biologics (Shanghai) and curren...

DB-1310 by Duality Biologics (Shanghai) for Human Epide...

Dec 6, 2023

DB-1310 is under clinical development by Duality Biologics (Shanghai) and curren...

STAT+: BIO selects rare disease advocate, biotech executive John Crowley as new CEO

STAT+: BIO selects rare disease advocate, biotech execu...

Dec 5, 2023

BIO’s new CEO, John Crowley, is a longtime board member — and the inspiration fo...

STAT+: Pharmalittle: CVS to overhaul how it’s paid for drugs; Biden drug-shortage plan won’t expand chemo supplies

STAT+: Pharmalittle: CVS to overhaul how it’s paid for ...

Dec 5, 2023

CVS, the nation’s largest drugstore chain, will move away from the complex formu...

STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research

STAT+: J&J to emphasize cancer drugs and stop much of i...

Dec 5, 2023

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emp...